Table 4 SRS and SBRT treatment indication and characteristics
Variable (N) | N (%) |
|---|---|
SRS/SBRT treatment indication (11072) | Â |
      Primary treatment | 7748 (70.0%) |
      Adjuvant treatment | 1585 (14.3%) |
      Non-surgical boost | 1077 (9.7%) |
      Post-operative treatment | 231 (2.1%) |
      Post-operative for residual tumor | 336 (3.0%) |
      Post-operative for cavity boost | 83 (0.7%) |
      Pre-operative treatment | 12 (0.1%) |
SRS/SBRT treatment objective (11072) | Â |
      Curative | 4407 (39.8%) |
      Palliative | 4958 (44.8%) |
      Other | 564 (5.1%) |
      Not reported | 1461 (12%) |
Mean lesion volume, range (5890) | 33.67 (0–5255 cc) |
Median lesion size in x,y,z, mm | 27.2, 24.6, 24.9 |
Median number of fiducials (range) | 1 (1–9) |
Median number of fractions (range) | 3 (0–46) |
Median prescription dose, range (8585) | 30 (0 – 96.7 Gy) |
Median maximum point dose, range (7953) | 40.98 (0–100 Gy) |
Most common collimator size, intracranial lesion | 10Â mm |
Most common collimator size, extracranial lesion | 20Â mm |